MX349548B - Compuestos de tienopirimidina. - Google Patents

Compuestos de tienopirimidina.

Info

Publication number
MX349548B
MX349548B MX2014008155A MX2014008155A MX349548B MX 349548 B MX349548 B MX 349548B MX 2014008155 A MX2014008155 A MX 2014008155A MX 2014008155 A MX2014008155 A MX 2014008155A MX 349548 B MX349548 B MX 349548B
Authority
MX
Mexico
Prior art keywords
thienopyrimidine compounds
compounds
thienopyrimidine
immune
auto
Prior art date
Application number
MX2014008155A
Other languages
English (en)
Other versions
MX2014008155A (es
Inventor
Cornelius Hermann Johannes
Padilla Fernando
Chen Shaoqing
T Le Nam
C Lucas Matthew
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014008155A publication Critical patent/MX2014008155A/es
Publication of MX349548B publication Critical patent/MX349548B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se refiere al uso de nuevos compuestos de la Fórmula I: (ver Fórmula) en donde todos los sustituyentes variables se definen como se describen en la presente, los cuales son inhibidores de SYK y son útiles para el tratamiento de enfermedades auto-inmunes e inflamatorias.
MX2014008155A 2012-01-10 2013-01-07 Compuestos de tienopirimidina. MX349548B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584863P 2012-01-10 2012-01-10
PCT/EP2013/050139 WO2013104575A1 (en) 2012-01-10 2013-01-07 Thienopyrimidine compounds

Publications (2)

Publication Number Publication Date
MX2014008155A MX2014008155A (es) 2014-10-14
MX349548B true MX349548B (es) 2017-08-02

Family

ID=47553050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008155A MX349548B (es) 2012-01-10 2013-01-07 Compuestos de tienopirimidina.

Country Status (11)

Country Link
US (1) US9701691B2 (es)
EP (1) EP2802590B1 (es)
JP (1) JP6109193B2 (es)
KR (1) KR20140110066A (es)
CN (1) CN104159904B (es)
BR (1) BR112014016710A8 (es)
CA (1) CA2860548A1 (es)
HK (1) HK1203933A1 (es)
MX (1) MX349548B (es)
RU (1) RU2637925C2 (es)
WO (1) WO2013104575A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012130780A1 (en) * 2011-03-28 2012-10-04 F. Hoffmann-La Roche Ag Thiazolopyrimidine compounds
AU2015204566A1 (en) * 2014-01-09 2016-08-25 Intra-Cellular Therapies, Inc. Organic compounds
KR20200084899A (ko) * 2017-11-30 2020-07-13 한미약품 주식회사 단백질 키나제에 대한 억제 활성을 갖는 티에노[3,2-d]피리미딘 화합물
JP7198820B2 (ja) * 2017-12-15 2023-01-04 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110183464B (zh) * 2019-05-31 2021-08-31 淮阴工学院 一种抗癌化合物艾斯替尼及其合成方法和应用
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022015938A1 (en) * 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522853A (ja) * 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
JPWO2002026745A1 (ja) * 2000-09-29 2004-02-05 日本曹達株式会社 チエノピリミジン化合物とその塩並びに製造方法
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JPWO2005095419A1 (ja) 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
WO2008059368A2 (en) 2006-11-17 2008-05-22 Pfizer Products Inc. Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
GB0718432D0 (en) 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
EP2215093B1 (de) * 2007-10-19 2011-12-14 Boehringer Ingelheim International GmbH Neue piperazino-dihydrothienopyrimidin-derivate
EP3109249A1 (en) 2007-11-15 2016-12-28 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
JP5675614B2 (ja) * 2008-08-26 2015-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のチエノピリミジン
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
KR101094446B1 (ko) * 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
JP2013519044A (ja) * 2010-02-08 2013-05-23 ナショナル ウィンド エナジー カンパニー リミテッド 垂直軸盤式発電機用磁気浮上支持構造とそれを用いた垂直軸盤式発電機
MX358682B (es) * 2010-07-13 2018-08-31 Hoffmann La Roche Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).

Also Published As

Publication number Publication date
JP6109193B2 (ja) 2017-04-05
BR112014016710A8 (pt) 2017-07-04
EP2802590A1 (en) 2014-11-19
KR20140110066A (ko) 2014-09-16
US9701691B2 (en) 2017-07-11
HK1203933A1 (en) 2015-11-06
MX2014008155A (es) 2014-10-14
BR112014016710A2 (pt) 2017-06-13
CN104159904A (zh) 2014-11-19
US20130178460A1 (en) 2013-07-11
CN104159904B (zh) 2016-12-14
RU2637925C2 (ru) 2017-12-08
CA2860548A1 (en) 2013-07-18
RU2014131367A (ru) 2016-02-27
JP2015503576A (ja) 2015-02-02
WO2013104575A1 (en) 2013-07-18
EP2802590B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
MX343561B (es) Compuestos de imidazolpiridazina.
MX352928B (es) Compuestos de piridazina-amida.
MX342310B (es) Compuestos de tiazolopirimidina.
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
PH12017502141A1 (en) Compounds and their methods of use
MX349548B (es) Compuestos de tienopirimidina.
MX2015001207A (es) Compuestos de heteroarilo y heterociclo novedosos, composición y métodos de los mismos.
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
PH12016500225B1 (en) Novel quinoline-substituted compound
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
JO3722B1 (ar) مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
NZ711192A (en) Process for making benzoxazepin compounds
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
WO2014086453A8 (en) Azaheterobicyclic compounds
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
IN2015DN00950A (es)
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.

Legal Events

Date Code Title Description
FG Grant or registration